Investor Alert

New York Markets Open in:

Replimune Group Inc.

NAS: REPL

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 25, 2022, 4:16 p.m.

/zigman2/quotes/203971249/composite

$

19.08

Change

-0.91 -4.55%

Volume

Volume 1,094

Quotes are delayed by 20 min

/zigman2/quotes/203971249/composite

Previous close

$ 19.57

$ 19.99

Change

+0.42 +2.15%

Day low

Day high

$19.31

$20.07

Open

52 week low

52 week high

$13.05

$30.89

Open

Company Description

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the abi...

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Valuation

Price to Book Ratio

1.95

Enterprise Value to EBITDA

-5.40

Efficiency

Liquidity

Current Ratio

19.46

Quick Ratio

19.46

Cash Ratio

19.06

Profitability

Return on Assets

-23.51

Return on Equity

-25.94

Return on Total Capital

-24.89

Capital Structure

Total Debt to Total Assets

7.12

Officers and Executives

Name Age Officer Since Title
Dr. Robert Coffin 54 2015 President & Director
Mr. Philip Astley-Sparke 50 2015 Executive Chairman
Dr. Colin A. Love 62 2015 Chief Operating Officer
Ms. Jean M. Franchi 54 2019 Chief Financial Officer, Secretary & Treasurer
Ms. Tanya N. Lewis 50 2020 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/16/2022 Robert Coffin
President & Chief R&D Officer; Director
5,737   Disposition at $14.59 per share. 83,702
05/16/2022 Philip Astley-Sparke
Chief Executive Officer; Director
9,632   Disposition at $14.59 per share. 140,530
05/16/2022 Colin A. Love
Chief Operating Officer
6,324   Disposition at $14.59 per share. 92,267
05/16/2022 Pamela Esposito
Chief Business Officer
3,507   Disposition at $14.59 per share. 51,167
05/16/2022 Sushil Patel
Chief Commercial Officer
10,687   Disposition at $14.59 per share. 155,923
05/16/2022 Tanya N. Lewis
Chief Dev. Op Officer
5,473   Disposition at $14.59 per share. 79,851
05/16/2022 Jean M. Franchi
Chief Financial Officer
3,436   Disposition at $14.59 per share. 50,131
04/01/2022 Robert Coffin
President & Chief R&D Officer; Director
26,250   Award at $0 per share. 0
04/01/2022 Philip Astley-Sparke
Chief Executive Officer; Director
70,000   Award at $0 per share. 0
04/01/2022 Colin A. Love
Chief Operating Officer
26,250   Award at $0 per share. 0
04/01/2022 Pamela Esposito
Chief Business Officer
22,750   Award at $0 per share. 0
04/01/2022 Sushil Patel
Chief Commercial Officer
52,500   Award at $0 per share. 0
04/01/2022 Tanya N. Lewis
Chief Dev. Op Officer
52,500   Award at $0 per share. 0
04/01/2022 Jean M. Franchi
Chief Financial Officer
52,500   Award at $0 per share. 0
03/16/2022 Omega Fund Management LLC
38,762   Disposition at $15.55 per share. 602,749
03/16/2022 Omega Fund Management LLC
6,238   Disposition at $15.31 per share. 95,503
03/15/2022 Omega Fund Management LLC
45,000   Disposition at $15.64 per share. 703,800
03/14/2022 Omega Fund Management LLC
16,500   Disposition at $15.42 per share. 254,430
03/14/2022 Omega Fund Management LLC
16,500   Derivative/Non-derivative trans. at $9.78 per share. 161,370
11/22/2021 Omega Fund Management LLC
10,162   Disposition at $34.7 per share. 352,621
11/19/2021 Omega Fund Management LLC
417   Disposition at $34.8 per share. 14,511
11/19/2021 Omega Fund Management LLC
34,845   Disposition at $34.54 per share. 1,203,546
11/18/2021 Omega Fund Management LLC
2,441   Disposition at $33.5 per share. 81,773
11/18/2021 Omega Fund Management LLC
2,441   Disposition at $33.5 per share. 81,773
11/16/2021 Omega Fund Management LLC
153   Disposition at $33.5 per share. 5,125
11/16/2021 Omega Fund Management LLC
153   Disposition at $33.5 per share. 5,125
11/15/2021 Omega Fund Management LLC
782   Disposition at $33.66 per share. 26,322
/news/latest/company/us/repl

MarketWatch News on REPL

  1. Novavax Inc. stock rises Wednesday, still underperforms market

    5:14 p.m. Nov. 23, 2022

    - MarketWatch Automation

  2. Novavax Inc. stock falls Tuesday, underperforms market

    5:13 p.m. Nov. 22, 2022

    - MarketWatch Automation

  3. Novavax Inc. stock falls Monday, underperforms market

    5:13 p.m. Nov. 21, 2022

    - MarketWatch Automation

  4. Novavax Inc. stock falls Friday, underperforms market

    5:13 p.m. Nov. 18, 2022

    - MarketWatch Automation

  5. Novavax Inc. stock falls Thursday, underperforms market

    5:13 p.m. Nov. 17, 2022

    - MarketWatch Automation

  6. Novavax Inc. stock underperforms Wednesday when compared to competitors

    5:13 p.m. Nov. 16, 2022

    - MarketWatch Automation

  7. Novavax Inc. stock rises Tuesday, still underperforms market

    5:13 p.m. Nov. 15, 2022

    - MarketWatch Automation

  8. Novavax Inc. stock underperforms Monday when compared to competitors

    5:13 p.m. Nov. 14, 2022

    - MarketWatch Automation

  9. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. Feb. 11, 2022

    - MarketWatch Automation

  10. Novavax Inc. stock falls Thursday, underperforms market

    5:13 p.m. Feb. 10, 2022

    - MarketWatch Automation

  11. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. Feb. 9, 2022

    - MarketWatch Automation

  12. Novavax Inc. stock underperforms Tuesday when compared to competitors

    5:13 p.m. Feb. 8, 2022

    - MarketWatch Automation

  13. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. Feb. 7, 2022

    - MarketWatch Automation

  14. Novavax Inc. stock rises Friday, still underperforms market

    5:14 p.m. Feb. 4, 2022

    - MarketWatch Automation

  15. Novavax Inc. stock outperforms market despite losses on the day

    5:14 p.m. Feb. 3, 2022

    - MarketWatch Automation

  16. Novavax Inc. stock falls Wednesday, underperforms market

    5:14 p.m. Feb. 2, 2022

    - MarketWatch Automation

  17. Novavax Inc. stock rises Tuesday, outperforms market

    5:14 p.m. Feb. 1, 2022

    - MarketWatch Automation

  18. Novavax Inc. stock rises Monday, outperforms market

    5:14 p.m. Jan. 31, 2022

    - MarketWatch Automation

  19. Novavax Inc. stock outperforms market on strong trading day

    5:14 p.m. Jan. 28, 2022

    - MarketWatch Automation

  20. Novavax Inc. stock underperforms Thursday when compared to competitors

    5:14 p.m. Jan. 27, 2022

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/repl

Other News on REPL

  1. 10-Q: REPLIMUNE GROUP, INC.

    7:18 a.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. Replimune secures $200M term loan

    7:09 a.m. Oct. 7, 2022

    - Seeking Alpha

  3. Replimune: Recent Developments Strengthen Bull Thesis

    5:26 p.m. Aug. 12, 2022

    - Seeking Alpha

  4. 10-Q: REPLIMUNE GROUP, INC.

    7:16 a.m. Aug. 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. 10-K: REPLIMUNE GROUP, INC.

    7:14 a.m. May 19, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

    3:23 p.m. March 8, 2022

    - Seeking Alpha

  7. 10-Q: REPLIMUNE GROUP, INC.

    8:21 a.m. Feb. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Replimune: In The 'Buy Zone' Again

    2:58 p.m. Oct. 1, 2021

    - Seeking Alpha

  9. Replimune Group EPS misses by $0.08

    8:14 a.m. Aug. 6, 2021

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

Replimune Group, Inc.

500 Unicorn Park Drive

3rd floor

Woburn, Massachusetts 01801

Phone

1 7812229600

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

03/2023

Revenue

N/A

Net Income

$-118.04M

Employees

206.00

/news/pressrelease/company/us/repl

Press Releases on REPL

  1. Replimune to Host Virtual Investor Event on December 7, 2022

    8:00 a.m. Nov. 22, 2022

    - GlobeNewswire

  2. Replimune to Present at Two Upcoming Investor Conferences

    3:01 p.m. Nov. 2, 2022

    - GlobeNewswire

  3. Replimune to Present at Two Upcoming Investor Conferences

    3:01 p.m. Aug. 1, 2022

    - GlobeNewswire

  4. Replimune to Present at the Jefferies Healthcare Conference

    7:00 a.m. June 2, 2022

    - GlobeNewswire

  5. Replimune to Host Virtual Investor Event on March 30, 2022

    7:00 a.m. March 21, 2022

    - GlobeNewswire

  6. Replimune Appoints Christy Oliger to its Board of Directors

    8:01 a.m. Dec. 2, 2021

    - GlobeNewswire

  7. Loading more headlines...
Link to MarketWatch's Slice.